J.P. Morgan Asset Management today released its seventh annual Global Alternatives Outlook, providing a 12-to-18 month ...

Radiotherapy, China's biotech surge and AI's role in drug discovery are notable topics that emerged from conversations on the ...

What are biopharma VCs looking to invest in this year? Autoimmune disorders, osteoporosis, and cardiovascular disease are ...

Boss also lowered his FY gross margin to 58.8%, representing a 70-basis point decline year-over-year, attributed to headwinds ...

Kaguya Komatsu has been named the first female CEO of J.P. Morgan Asset Management -Japan, succeeding Shoichi Ohkoshi, who ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

J.P.Morgan estimated spending on data centers could contribute between 10-20 basis points to U.S. economic growth in ...

Jamie Dimon, chairman and CEO, noted in the release that in the asset and wealth management division client net inflows ...

J.P. Morgan analyst Ranjan Sharma maintained a Buy rating on Grab (GRAB – Research Report) on January 21 and set a price target of $5.60. The ...

Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...

J.P. Morgan analyst John Royall maintained a Sell rating on Murphy USA (MUSA – Research Report) on January 16 and set a price target of $431.00. The company’s shares closed last Friday at $476.29.

J.P. Morgan Healthcare Conference is officially underway, bringing the healthcare and biopharma industries' biggest wheelers ...